Abstract Alzheimer’s disease is the most common neurodegenerative disease. Prior to 2017, National Medical Products Administration approved only four drugs…
Abstract Corticobasal syndrome (CBS) is a clinical syndrome characterised by progressive asymmetric limb rigidity and apraxia with dystonia, myoclonus, cortical…
Abstract The rigid core of intracellular tau filaments from Alzheimer’s disease (AD), Pick’s disease (PiD), and Corticobasal disease (CBD) brains…
Abstract Genome‐wide association studies have described several genes as genetic susceptibility loci for Alzheimer’s disease (AD). Among them, CD2AP encodes…
Abstract Aims: This study aimed to develop a deep learning‐based model for differentiating tauopathies, including Alzheimer’s disease (AD), progressive supranuclear…
Abstract Agitation is a behavioral syndrome characterized by increased, often undirected, motor activity, restlessness, aggressiveness, and emotional distress. According to…
Abstract Introduction: There is increasing emphasis on the importance of optimizing and standardizing clinical trials of agitation in Alzheimer’s disease…
Abstract Alzheimer’s disease (AD) is a neurodegenerative disorder which accounts for 60–70% of the 50 million worldwide cases of dementia…
Abstract The endocannabinoid system (ECS) has received extensive attention for its neuroprotective effect on the brain. This system comprises endocannabinoids,…
Abstract Cannabis sativa, commonly known as marijuana, contains a pool of secondary plant metabolites with therapeutic effects. Besides Δ9-tetrahydrocannabinol that…